Polaris Partners

Portfolio Co Investors 2026 for Polaris Partners: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Polaris Partners accounts for 60 tracked companies with verified cap-table data, 60 of which disclose round sizes totalling $12B. The median disclosed raise is $123M, and the largest is Morphic Therapeutic at $3.2B, ahead of Moderna ($650M) and ReCode Therapeutics ($570M).

The names that recur most often on these co-invested cap tables are Polaris Partners (60 companies), ARCH Venture Partners (9 companies), GV (9 companies), Alexandria Venture Investments (8 companies), Vida Ventures (7 companies), Leaps by Bayer (7 companies). By latest disclosed round, the market skews Series A (20), Series B (15), Series D (7), Series C (7).

Best funded Polaris Partners companies

  1. Morphic Therapeutic — $3.2B (latest: Series B)
  2. Moderna — $650M (latest: Series G)
  3. ReCode Therapeutics — $570M (latest: Series B)
  4. Neumora Therapeutics — $500M (latest: Series A)
  5. EGenesis — $481M (latest: Series D)
  6. Iora Health — $350M (latest: Series F)
  7. Dewpoint Therapeutics — $287M (latest: Series C)
  8. Triveni Bio — $277M (latest: Series C)
  9. 1366 Technologies — $265M (latest: Series E)
  10. AgBiome — $236M (latest: Series D)
  11. Semisic — $222M (latest: Series B)
  12. Tome Biosciences — $213M (latest: Series B)
  13. Nuvig Therapeutics — $208M (latest: Series B)
  14. SQZ Biotech — $200M (latest: Series D)
  15. Soufflé Therapeutics — $200M (latest: Series A)

Polaris Partners — related firms and companies (56)

Polaris Partners profile · All research reports